Talaris Therapeutics (NASDAQ:TALS) Versus Genocea Biosciences (NASDAQ:GNCAQ) Head-To-Head Contrast
Talaris Therapeutics (NASDAQ:TALS) Versus Genocea Biosciences (NASDAQ:GNCAQ) Head-To-Head Contrast
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
塔拉里斯治療 (NASDAQ: TALS-獲得評級) 和基諾西亞生物科學 (NASDAQ: GNCAQ — 獲取評級) 都是小型股醫療公司, 但這是優越的業務?我們將根據兩家公司的股息，分析師建議，機構所有權，風險，盈利能力，盈利能力，收益和估值來對比兩家公司。
Volatility & Risk
波動性和風險
Talaris Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
塔拉瑞斯治療的測試版為 2.19，這意味著其股價比標普 500 的波動性高 119％。相對而言，基諾西亞生物科學的測試版為 2.03，這意味著其股價比標普 500 更具波動性 103%。
Insider and Institutional Ownership
內幕和機構所有權
65.4% of Talaris Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 16.6% of Talaris Therapeutics shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
65.4% 的塔拉瑞治療股份由機構投資者持有。相比之下，0.6％ 的 Genocea 生物科學股份由機構投資者持有。16.6％ 的塔拉里斯治療股份由公司內部人員持有。相比之下，1.6％ 的 Genocea 生物科學股份由公司內部人員持有。強大的機構所有權表明，大型資金經理，對沖基金和捐贈基金認為股票有望實現長期增長。
Analyst Recommendations
分析師推薦
This is a breakdown of recent ratings and price targets for Talaris Therapeutics and Genocea Biosciences, as reported by MarketBeat.
據 MarketBeat 報導，這是塔拉里斯療法和基那歐西亞生物科學的近期評級和價格目標的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talaris Therapeutics | 0 | 2 | 1 | 0 | 2.33 |
| Genocea Biosciences | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 塔拉里斯治療 | 0 | 2 | 1 | 0 | 2.33 |
| 赫諾西亞生物科學 | 0 | 0 | 0 | 0 | N/A |
Talaris Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 584.21%.
塔拉里斯治療目前的共識價格目標為 13.00 美元，表明潛在的上行空間為 584.21％。
Valuation and Earnings
估值及收益
This table compares Talaris Therapeutics and Genocea Biosciences' gross revenue, earnings per share (EPS) and valuation.
此表比較了塔拉里斯治療和吉那歐斯生物科學的總收入，每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talaris Therapeutics | N/A | N/A | -$47.83 million | ($1.66) | -1.14 |
| Genocea Biosciences | $1.64 million | 0.00 | -$33.20 million | ($0.61) | N/A |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 塔拉里斯治療 | N/A | N/A | -4.783 萬元 | (一百六十六元) | -1.14 |
| 赫諾西亞生物科學 | 一百六十四萬元 | 0.00 | -33.2 億美元 | (0.61 美元) | N/A |
Genocea Biosciences has higher revenue and earnings than Talaris Therapeutics. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
基諾西亞生物科學比塔拉里斯治療藥物具有更高的收入和收入。與 Genocea 生物科學相比，塔拉里斯治療以較低的價格與收益比進行交易，這表明它目前兩隻股票中價格更便宜。
Profitability
盈利
This table compares Talaris Therapeutics and Genocea Biosciences' net margins, return on equity and return on assets.
此表格比較了塔拉里斯治療和 Genocea 生物科學的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Talaris Therapeutics | N/A | -31.84% | -30.39% |
| Genocea Biosciences | N/A | N/A | N/A |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 塔拉里斯治療 | N/A | -31.84% | -30.39% |
| 赫諾西亞生物科學 | N/A | N/A | N/A |
Summary
摘要
Genocea Biosciences beats Talaris Therapeutics on 6 of the 10 factors compared between the two stocks.
赫諾西亞生物科學擊敗塔拉里斯療法上 6 的 10 因素兩個股票之間的比較.
About Talaris Therapeutics
關於塔拉瑞斯治療
(Get Rating)
(取得評分)
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
塔拉里斯治療有限公司在美國是一家後期臨床階段細胞治療公司。該公司致力於開發一種異體造血幹細胞移植方法，以改變固體器官移植和嚴重自身免疫性疾病以及嚴重的非惡性血液，免疫和代謝疾病的護理標準。其主要候選產品是 FCR001，這是一種新型異體細胞療法，正在為活體供體腎移植患者進行 II 期試驗。該公司還在死者的供體腎移植中開發 FCR002; FCR001 用於嚴重形式硬皮病患者; FCR001 用於一種或多種嚴重的非惡性血液，免疫或代謝紊亂。塔拉里斯治療有限公司成立於 1988 年，總部位於肯塔基州的路易斯維爾。
About Genocea Biosciences
關於基諾西亞生物科學
(Get Rating)
(取得評分)
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Genocea 生物科學公司從事癌症免疫療法的開發和商業化。該公司使用其專有技術平台 ATLAS，根據實際的人體免疫反應來識別 T 細胞與臨床相關的抗原。其候選產品包括 GEN-011（一種研究性採用性 T 細胞療法）和 GEN-009（一種新抗原癌症疫苗）。該公司由羅伯特·保爾和凱文·比特曼於 2006 年 8 月 16 日成立，總部位於麻薩諸塞州劍橋。
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收塔拉里斯治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊獲取有關 Talaris 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。